BR112017020961A2 - muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação - Google Patents

muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação

Info

Publication number
BR112017020961A2
BR112017020961A2 BR112017020961-6A BR112017020961A BR112017020961A2 BR 112017020961 A2 BR112017020961 A2 BR 112017020961A2 BR 112017020961 A BR112017020961 A BR 112017020961A BR 112017020961 A2 BR112017020961 A2 BR 112017020961A2
Authority
BR
Brazil
Prior art keywords
mutein
proteins
nucleic acid
host cell
acid molecule
Prior art date
Application number
BR112017020961-6A
Other languages
English (en)
Inventor
Hinner Marlon
Allersdorfer Andrea
Siham Bel Aiba Rachida
Aloe Michaela
Wiedenmann Alexander
Matschiner Gabriele
Huelsmeyer Martin
Original Assignee
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh filed Critical Pieris Pharmaceuticals Gmbh
Publication of BR112017020961A2 publication Critical patent/BR112017020961A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)

Abstract

a presente divulgação diz respeito a novas proteínas terapêuticas e/ou de diagnóstico de ligação específica direcionadas contra glipican-3 (gpc3), cujas proteínas são preferencialmente muteínas de uma proteína lipocalina, mais preferencialmente da lipocalina 2 (lcn2 ou ngal). a presente divulgação também diz respeito às moléculas de ácido nucleico que codificam tais proteínas e aos métodos para geração e uso de tais proteínas e moléculas de ácido nucleico. consequentemente, a presente divulgação também é destinada a composições farmacêuticas e/ou de diagnóstico que compreendem tais proteínas de lipocalina, incluindo as utilizações destas proteínas.
BR112017020961-6A 2015-05-18 2016-05-18 muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação BR112017020961A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15167922.2 2015-05-18
EP15167922 2015-05-18
PCT/EP2016/061058 WO2016184875A1 (en) 2015-05-18 2016-05-18 Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)

Publications (1)

Publication Number Publication Date
BR112017020961A2 true BR112017020961A2 (pt) 2018-07-10

Family

ID=53180583

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020961-6A BR112017020961A2 (pt) 2015-05-18 2016-05-18 muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação

Country Status (13)

Country Link
US (2) US10273275B2 (pt)
EP (1) EP3298029A1 (pt)
JP (2) JP6942060B2 (pt)
KR (1) KR20180008649A (pt)
CN (2) CN114456252A (pt)
AU (1) AU2016262838B2 (pt)
BR (1) BR112017020961A2 (pt)
CA (1) CA2982034A1 (pt)
MX (1) MX2017014730A (pt)
RU (1) RU2756318C2 (pt)
SG (1) SG11201707872WA (pt)
WO (1) WO2016184875A1 (pt)
ZA (1) ZA201706605B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549968B2 (en) 2009-12-07 2017-01-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
EP3789397B1 (en) 2014-05-22 2023-12-06 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
EP3250586B1 (en) 2015-01-28 2021-10-27 Pieris Pharmaceuticals GmbH Novel proteins specific for angiogenesis
WO2016177762A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN107636014B (zh) 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
ES2938525T3 (es) * 2015-05-18 2023-04-12 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anticanceroso
EP3298029A1 (en) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
US10703810B2 (en) 2015-11-30 2020-07-07 Pieris Australia Pty Ltd. Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
SG11202106353VA (en) 2019-02-26 2021-07-29 Pieris Pharmaceuticals Gmbh Novel fusion proteins specific for cd137 and gpc3
JP2022526367A (ja) 2019-03-29 2022-05-24 ピエリス ファーマシューティカルズ ゲーエムベーハー リポカリンムテインの吸入投与
CA3177098A1 (en) 2020-06-05 2021-12-09 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE69534318T2 (de) 1994-05-18 2006-04-20 Nektar Therapeutics, San Carlos Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (fr) 1996-10-14 1998-04-23 Firm Forsat Ltd. Procede de preparation de dispersions a base de composants chromogenes
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
SI1087778T1 (sl) 1998-06-08 2006-02-28 Hoffmann La Roche Uporaba peg-ifn-alfa in ribavirina za zdravljenje kronicnega hepatitisa c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7235520B2 (en) 2000-09-21 2007-06-26 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
ES2373055T3 (es) * 2005-08-09 2012-01-31 Oncotherapy Science, Inc. Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US8598317B2 (en) * 2006-03-20 2013-12-03 Technische Universitaet Muenchen Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
CA2659413C (en) 2006-08-01 2016-06-14 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
PT2178921E (pt) 2007-07-17 2016-03-23 Squibb & Sons Llc Anticorpos monoclonais contra glipicano-3
CA2702611A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Immunoassays and kits for the detection of ngal
AU2009264214B2 (en) 2008-06-24 2013-06-06 Technische Universitaet Muenchen Muteins of hNGAL and related proteins with affinity for a given target
US9549968B2 (en) * 2009-12-07 2017-01-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
TR201906295T4 (tr) 2010-06-08 2019-05-21 Astrazeneca Ab IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri.
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
AU2011331232B2 (en) * 2010-11-15 2015-05-07 Pieris Ag Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
US20130225505A1 (en) 2011-11-23 2013-08-29 Allergan, Inc. Muteins of human tear lipcalin for treating neovascular disease of the anterior segment of the human eye
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
EP2920202B1 (en) * 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
EP3250586B1 (en) 2015-01-28 2021-10-27 Pieris Pharmaceuticals GmbH Novel proteins specific for angiogenesis
JP6843754B2 (ja) 2015-02-18 2021-03-17 ピエリス ファーマシューティカルズ ゲーエムベーハー ピオベルジン及びピオケリンに特異的な新規なタンパク質
WO2016177762A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
EP3298029A1 (en) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)

Also Published As

Publication number Publication date
JP2018519802A (ja) 2018-07-26
SG11201707872WA (en) 2017-10-30
KR20180008649A (ko) 2018-01-24
CN114456252A (zh) 2022-05-10
WO2016184875A1 (en) 2016-11-24
JP2021184725A (ja) 2021-12-09
US20190309037A1 (en) 2019-10-10
RU2017135605A (ru) 2019-06-18
CN107787327B (zh) 2022-02-08
MX2017014730A (es) 2018-06-28
JP7217783B2 (ja) 2023-02-03
AU2016262838B2 (en) 2020-10-08
CN107787327A (zh) 2018-03-09
RU2017135605A3 (pt) 2019-11-13
RU2756318C2 (ru) 2021-09-29
AU2016262838A1 (en) 2018-01-04
JP6942060B2 (ja) 2021-09-29
US20180141988A1 (en) 2018-05-24
ZA201706605B (en) 2020-05-27
EP3298029A1 (en) 2018-03-28
US10787491B2 (en) 2020-09-29
US10273275B2 (en) 2019-04-30
CA2982034A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
BR112017020961A2 (pt) muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação
BR112017015773A2 (pt) muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
BR112018000835A2 (pt) molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
BR112016030424A2 (pt) construções de anticorpo multiespecíficas
BR112018000366A2 (pt) polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
BR112016027024A2 (pt) polipeptídeos de ligação específica e seus usos
BR112017020445A2 (pt) polipeptídeo de fusão, molécula de ácido nucleico, célula hospedeira, método de produção de um polipeptídeo de fusão, uso do polipeptídeo de fusão, método para ativar as vias de sinalização, método para coestimular células, método para induzir a proliferação de linfócitos e método para direcionar o agrupamento de cd137
UY32607A (es) Mutantes de fgf21 y usos del mismo
BR112017007093A2 (pt) composições e métodos de uso para aumento da resposta imune e terapia do câncer
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BRPI1013877A2 (pt) Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
BR112015017800A2 (pt) moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t
BR112016030462A2 (pt) moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo
BR112019009106A2 (pt) método para aumentar os níveis de secreção sem afetar as funções biológicas de il-2 de humano recombinante e suas proteínas mutantes derivadas, proteínas obtidas, e, usos do método e das proteínas obtidas
BR112015019879A2 (pt) Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas
BR112012029588A2 (pt) materiais biológicas relacionados a her3.
BR112016029906A2 (pt) compostos excipientes redutores de viscosidade para formulações proteicas
CO6341566A2 (es) Mutantes fgf21 y usos de de los mismos
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]